https://www.pharmaradar360.com/article/the-acta-just-got-an-upgrade-d847f71c5d67e575Pharma Surgeen2026-07-01T16:18:24.000ZThe ACTA Just Got an Upgradehttps://www.pharmaradar360.com/article/medicare-will-spend-more-than-13-billion-on-the-medicare-advantage-quality-bonus-2a82a6a0bff86a8dPharma Surgeen2026-07-01T16:15:00.000ZMedicare Will Spend More Than $13 Billion on the Medicare Advantage Quality Bonus Program in 2026https://www.pharmaradar360.com/article/decoding-medicare-advantage-coding-intensity-74892946070d5963Pharma Surgeen2026-07-01T16:15:00.000ZDecoding Medicare Advantage Coding Intensityhttps://www.pharmaradar360.com/article/carolina-s-school-of-data-and-information-sciences-launches-3bcc4095492be6abPharma Surgeen2026-07-01T16:10:40.000ZCarolina’s School of Data and Information Sciences launcheshttps://www.pharmaradar360.com/article/collaboration-is-key-for-carolina-s-newest-school-d3925202e1effa31Pharma Surgeen2026-07-01T16:09:09.000ZCollaboration is key for Carolina’s newest schoolhttps://www.pharmaradar360.com/article/10-million-gift-launches-statewide-effort-to-expand-access-to-care-in-rural-alab-eff6204cc1984890Pharma Surgeen2026-07-01T16:07:53.000Z$10 million gift launches statewide effort to expand access to care in rural Alabamahttps://www.pharmaradar360.com/article/skin-cancer-risk-in-congenital-ichthyoses-how-all-of-us-data-supports-real-world-e7372772e9715505Pharma Surgeen2026-07-01T16:07:32.000ZSkin Cancer Risk in Congenital Ichthyoses: How All of Us Data Supports Real-World Rare Disease Researchhttps://www.pharmaradar360.com/article/oxford-researchers-become-embo-members-76884d7309bb0d70Pharma Surgeen2026-07-01T16:02:00.000ZOxford researchers become EMBO membershttps://www.pharmaradar360.com/article/jacob-smith-defies-early-prognosis-following-life-threatening-accident-664224178bee1dc0Pharma Surgeen2026-07-01T15:59:52.000ZJacob Smith defies early prognosis following life-threatening accidenthttps://www.pharmaradar360.com/article/medicare-s-glp-1-bridge-and-what-s-next-for-biotech-lly-nyse-4470e3b9b275cd47Pharma Surgeen2026-07-01T15:55:01.000ZMedicare's GLP-1 Bridge and what's next for biotech (LLY:NYSE)https://www.pharmaradar360.com/article/safe-use-of-electronic-devices-on-planes-3e53bd1d35dde82cPharma Surgeen2026-07-01T15:52:00.000ZSafe Use of Electronic Devices on Planeshttps://www.pharmaradar360.com/article/reliably-detecting-and-clearly-explaining-deepfake-images-dab264151fdd5c86Pharma Surgeen2026-07-01T15:52:00.000ZReliably Detecting and Clearly Explaining Deepfake Imageshttps://www.pharmaradar360.com/article/adressing-the-shortage-of-skilled-workers-with-lars-03b8c55e3a4c38adPharma Surgeen2026-07-01T15:52:00.000ZAdressing the Shortage of Skilled Workers With LARShttps://www.pharmaradar360.com/article/what-to-know-about-male-infertility-from-a-uab-urologist-9cc2608f34495905Pharma Surgeen2026-07-01T15:51:18.000ZWhat to know about male infertility from a UAB urologisthttps://www.pharmaradar360.com/article/teva-launches-hydrogen-truck-for-pharmaceutical-logistics-29d0fb0521d3abfdPharma Surgeen2026-07-01T15:50:00.000ZTeva Launches Hydrogen Truck for Pharmaceutical Logisticshttps://www.pharmaradar360.com/article/fda-recalls-and-warnings-foreign-substance-found-in-millions-of-prednisolone-bot-3d4bb5dbe80252bfPharma Surgeen2026-07-01T15:38:09.000ZFDA Recalls and Warnings: Foreign Substance Found in Millions of Prednisolone Bottles, Seizure Drug Mix-Up & Morehttps://www.pharmaradar360.com/article/extreme-heat-is-rising-and-so-is-the-risk-to-your-heart-72e193ae4bf3db81Pharma Surgeen2026-07-01T15:30:00.000ZExtreme heat is rising — and so is the risk to your hearthttps://www.pharmaradar360.com/article/quantumcell-commits-2-2bn-on-alzecure-s-alzheimer-s-platform-344766e0011da79ePharma Surgeen2026-07-01T15:27:52.000ZQuantumCell commits $2.2bn on AlzeCure’s Alzheimer’s platformhttps://www.pharmaradar360.com/article/how-amendment-intelligence-helps-reduce-avoidable-protocol-revisions-c9a94cbc3f8e1244Pharma Surgeen2026-07-01T15:27:20.000ZHow Amendment Intelligence Helps Reduce Avoidable Protocol Revisionshttps://www.pharmaradar360.com/article/guidance-mhra-innovation-office-guidance-and-support-e3617b6abf32ab4ePharma Surgeen2026-07-01T15:26:45.000ZGuidance: MHRA Innovation Office: guidance and supporthttps://www.pharmaradar360.com/article/pfas-free-coatings-for-mdi-canisters-what-to-look-for-92f6f285972821e8Pharma Surgeen2026-07-01T15:22:53.000ZPFAS-free coatings for MDI canisters: What to look forhttps://www.pharmaradar360.com/article/anthropic-debuts-ai-driven-pharma-r-d-tool-claude-science-56a0a3b20209f8d7Pharma Surgeen2026-07-01T15:22:30.000ZAnthropic debuts AI-driven pharma R&D tool, Claude Sciencehttps://www.pharmaradar360.com/article/bristol-myers-squibb-hires-lobbyist-on-drug-pricing-6fa0b056f7881fbePharma Surgeen2026-07-01T15:22:20.000ZBristol-Myers Squibb Hires Lobbyist on Drug Pricinghttps://www.pharmaradar360.com/article/postpartum-reintegration-an-uncomfortable-silence-pharmacy-can-no-longer-afford-8058a5c7f3fc1ebePharma Surgeen2026-07-01T15:15:54.000ZPostpartum reintegration: an uncomfortable silence pharmacy can no longer affordhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-welgene-biotech-co-ltd-tpex-6661-ba5b87640fd8ef80Pharma Surgeen2026-07-01T15:12:37.000ZPrice to earnings forward of Welgene Biotech Co., Ltd. – TPEX:6661https://www.pharmaradar360.com/article/devolved-governments-seen-to-favour-some-regions-e49247e1178d3a46Pharma Surgeen2026-07-01T14:59:25.000ZDevolved governments seen to favour some regionshttps://www.pharmaradar360.com/article/biophorum-unites-20-organizations-to-modernize-small-molecule-production-e2e4918eaded20e5Pharma Surgeen2026-07-01T14:53:53.000ZBioPhorum Unites 20 Organizations to Modernize Small Molecule Productionhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-stock-gains-12-in-three-months-here-s-why-bf1cf301b555f476Pharma Surgeen2026-07-01T14:41:00.000ZCollegium Pharmaceutical Stock Gains 12% in Three Months: Here's Whyhttps://www.pharmaradar360.com/article/programa-capes-augm-para-proyectos-conjuntos-de-investigacion-2026-y-2027-45bc240aa4549643Pharma Surgeen2026-07-01T14:36:13.000ZPrograma CAPES/AUGM para proyectos conjuntos de investigación 2026 Y 2027https://www.pharmaradar360.com/article/biotechs-in-better-position-to-avoid-workforce-reductions-as-layoffs-continue-to-14d96801d466744dPharma Surgeen2026-07-01T14:30:00.000ZBiotechs ‘in better position to avoid workforce reductions’ as layoffs continue to ease in Q2’26https://www.pharmaradar360.com/article/ipsen-to-buy-swiss-biotech-memo-therapeutics-in-potential-800m-deal-76355d597a466e75Pharma Surgeen2026-07-01T14:27:15.000ZIpsen to buy Swiss biotech Memo Therapeutics in potential $800M dealhttps://www.pharmaradar360.com/article/alzecure-pharma-enters-2-2-billion-licensing-and-collaboration-agreement-with-qu-451e97d9cb3f7782Pharma Surgeen2026-07-01T14:26:15.000ZAlzeCure Pharma Enters $2.2 Billion Licensing and Collaboration Agreement with QuantumCell ApShttps://www.pharmaradar360.com/article/what-s-really-driving-the-direct-to-patient-boom-929b73c93e4170c1Pharma Surgeen2026-07-01T14:25:20.000ZWhat's Really Driving the Direct-to-Patient Boom?https://www.pharmaradar360.com/article/medicines-packaging-labelling-and-patient-information-leaflets-c74904453a186685Pharma Surgeen2026-07-01T14:18:01.000ZMedicines: packaging, labelling and patient information leafletshttps://www.pharmaradar360.com/article/guidance-warning-statements-for-labels-and-leaflets-of-certain-medicines-647ee78898397083Pharma Surgeen2026-07-01T14:17:56.000ZGuidance: Warning statements for labels and leaflets of certain medicineshttps://www.pharmaradar360.com/article/guidance-best-practice-guidance-on-patient-information-leaflets-81f4119e573b76e0Pharma Surgeen2026-07-01T14:17:53.000ZGuidance: Best practice guidance on patient information leafletshttps://www.pharmaradar360.com/article/vamreg-disponible-a-partir-du-1-juillet-2026-debut-de-l-enregistrement-obligatoi-836b05034938ac9aPharma Surgeen2026-07-01T14:12:52.000ZVAMREG disponible à partir du 1 juillet 2026 : début de l’enregistrement obligatoire des antibiotiques à usage vétérinairehttps://www.pharmaradar360.com/article/one-step-closer-fda-removes-prohibitions-on-drug-testing-devices-build-america-2-f5cb765c9c5d9d64Pharma Surgeen2026-07-01T14:02:58.000ZOne step closer: FDA removes prohibitions on drug testing devices; BUILD America 250 pushes hair testinghttps://www.pharmaradar360.com/article/collegium-pharmaceutical-stock-gains-12-in-three-months-here-s-why-a102e20e329cf347Pharma Surgeen2026-07-01T14:02:32.000ZCollegium Pharmaceutical Stock Gains 12% in Three Months: Here's Whyhttps://www.pharmaradar360.com/article/american-heart-association-announces-volunteer-leaders-for-2026-27-44f1f7f168c50457Pharma Surgeen2026-07-01T14:00:00.000ZAmerican Heart Association announces volunteer leaders for 2026-27https://www.pharmaradar360.com/article/compras-y-contrataciones-bd7e1911203b8ea5Pharma Surgeen2026-07-01T13:57:09.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/centenario-de-spegazzini-visitas-guiadas-estreno-audiovisual-y-feria-fungi-8870fccbb0acedb9Pharma Surgeen2026-07-01T13:49:20.000ZCentenario de Spegazzini: visitas guiadas, estreno audiovisual y Feria Fungihttps://www.pharmaradar360.com/article/anthropic-launches-ai-initiative-for-life-sciences-7c8c8d93cbd744aaPharma Surgeen2026-07-01T13:48:45.000ZAnthropic launches AI initiative for life scienceshttps://www.pharmaradar360.com/article/protecting-temperature-integrity-in-extreme-heat-how-csafe-s-cold-chain-portfoli-96766acce2efa146Pharma Surgeen2026-07-01T13:40:54.000ZProtecting Temperature Integrity in Extreme Heat: How CSafe’s Cold Chain Portfolio Addresses the Riskhttps://www.pharmaradar360.com/article/more-signs-that-glp-1s-may-help-with-peripheral-artery-disease-92ac28f69f84b95fPharma Surgeen2026-07-01T13:40:39.000ZMore signs that GLP-1s may help with peripheral artery diseasehttps://www.pharmaradar360.com/article/eu-gefordertes-forschungsprojekt-zu-bauchspeicheldrusenkrebs-medizinische-fakult-7ddab42f47b10f3ePharma Surgeen2026-07-01T13:38:33.000ZEU-gefördertes Forschungsprojekt zu Bauchspeicheldrüsenkrebs: Medizinische Fakultät Heidelberg nimmt Schlüsselrolle einhttps://www.pharmaradar360.com/article/la-nouvelle-application-web-biovigilance-est-disponible-5e93ed530622a4a8Pharma Surgeen2026-07-01T13:29:58.000ZLa nouvelle application web BioVigilance est disponible !https://www.pharmaradar360.com/article/angitia-ends-phase-3-in-disc-disease-abivax-raises-800m-on-colitis-data-f4b385d383ebefcdPharma Surgeen2026-07-01T13:29:00.000ZAngitia ends Phase 3 in disc disease; Abivax raises $800M on colitis datahttps://www.pharmaradar360.com/article/surge-in-rmat-designations-awarded-by-the-fda-ada778bfba0a1922Pharma Surgeen2026-07-01T13:08:11.000ZSurge in RMAT designations awarded by the FDAhttps://www.pharmaradar360.com/article/prague-the-up-and-coming-biotech-hub-in-central-europe-c48ef67c994c5ddfPharma Surgeen2026-07-01T13:04:25.000ZPrague: The up-and-coming biotech hub in Central Europehttps://www.pharmaradar360.com/article/why-a-just-transition-to-a-more-sustainable-future-needs-better-law-e12a7337bbe9b8faPharma Surgeen2026-07-01T13:00:00.000ZWhy a just transition to a more sustainable future needs better lawhttps://www.pharmaradar360.com/article/33-jornadas-de-jovenes-investigadores-en-brasil-augm-508af5dec6ef963fPharma Surgeen2026-07-01T12:55:12.000Z33° Jornadas de Jóvenes Investigadores en Brasil (AUGM)https://www.pharmaradar360.com/article/covid-19-vaccine-boosters-may-help-protect-against-future-animal-coronaviruses-af72d116c77c6b0ePharma Surgeen2026-07-01T12:53:45.000ZCOVID-19 vaccine boosters may help protect against future animal coronaviruseshttps://www.pharmaradar360.com/article/biotech-startup-turns-to-space-to-manufacture-artificial-retinas-for-treating-bl-38ccb81ed82e5abePharma Surgeen2026-07-01T12:50:00.000ZBiotech Startup Turns to Space to Manufacture Artificial Retinas for Treating Blindnesshttps://www.pharmaradar360.com/article/running-for-science-and-better-health-kemri-s-inaugural-community-cross-country-38d374172c96e6d5Pharma Surgeen2026-07-01T12:46:40.000ZRunning for Science and Better Health: KEMRI’s Inaugural Community Cross Country Run Sets the Pace for Health Researchhttps://www.pharmaradar360.com/article/kemri-joins-initiative-to-strengthen-africa-s-next-generation-of-malaria-researc-3a73ce2a959ae06ePharma Surgeen2026-07-01T12:44:49.000ZKEMRI Joins Initiative to Strengthen Africa’s Next Generation of Malaria Research Leadershttps://www.pharmaradar360.com/article/amgen-or-biogen-which-biotech-stock-appears-better-poised-a63505cec977bdc9Pharma Surgeen2026-07-01T12:41:47.000ZAmgen or Biogen: Which Biotech Stock Appears Better Poised?https://www.pharmaradar360.com/article/tanti-auguri-pierina-100-anni-4e33f2841a32b8f4Pharma Surgeen2026-07-01T12:35:35.000ZTanti auguri Pierina, 100 anni!https://www.pharmaradar360.com/article/uk-must-do-more-on-access-to-rare-disease-medicines-says-abpi-96670e9e722f7dfbPharma Surgeen2026-07-01T12:34:15.000ZUK must do more on access to rare disease medicines, says ABPIhttps://www.pharmaradar360.com/article/partnerships-build-trust-between-industry-and-healthcare-professionals-aa249be27804f901Pharma Surgeen2026-07-01T12:34:15.000ZPartnerships build trust between industry and healthcare professionalshttps://www.pharmaradar360.com/article/public-attitudes-on-the-pharmaceutical-industry-will-increasing-familiarity-buil-b05c2353e306f48bPharma Surgeen2026-07-01T12:34:14.000ZPublic attitudes on the pharmaceutical industry: will increasing familiarity build confidence?https://www.pharmaradar360.com/article/international-comparisons-in-medicines-spending-and-the-link-to-competitiveness-81d855d6faa52709Pharma Surgeen2026-07-01T12:34:14.000ZInternational comparisons in medicines spending and the link to competitivenesshttps://www.pharmaradar360.com/article/trust-transparency-and-purpose-managing-reputation-in-a-challenging-environment-4ec78e119f5bf413Pharma Surgeen2026-07-01T12:34:14.000ZTrust, transparency and purpose – managing reputation in a challenging environmenthttps://www.pharmaradar360.com/article/familiarity-and-trust-why-it-matters-to-industry-reputation-and-what-we-can-we-d-f523a215ca3a2a2aPharma Surgeen2026-07-01T12:34:13.000ZFamiliarity and trust: Why it matters to industry reputation and what we can we do about ithttps://www.pharmaradar360.com/article/eli-lilly-s-40m-bet-on-ai-designed-injectable-antibody-sparks-36-rally-37ff8036a53d677fPharma Surgeen2026-07-01T12:31:50.000ZEli Lilly’s $40M Bet on AI-Designed Injectable Antibody Sparks 36% Rallyhttps://www.pharmaradar360.com/article/duloxetine-generic-cymbalta-recalled-over-potential-cancer-causing-compound-here-ef9c9c9277de982bPharma Surgeen2026-07-01T12:30:05.000ZDuloxetine (Generic Cymbalta) Recalled Over Potential Cancer-Causing Compound: Here Are the Lot Numbers to Checkhttps://www.pharmaradar360.com/article/amneal-s-new-u-s-sterile-manufacturing-facility-selected-for-fda-precheck-pilot-34e0f6ac120d3086Pharma Surgeen2026-07-01T12:30:00.000ZAmneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Programhttps://www.pharmaradar360.com/article/improved-early-warning-systems-needed-to-reduce-medicines-supply-risks-says-abpi-0ff9e3aab10402e7Pharma Surgeen2026-07-01T12:29:48.000ZImproved early warning systems needed to reduce medicines supply risks, says ABPIhttps://www.pharmaradar360.com/article/unlocking-nhs-data-to-increase-recruitment-into-clinical-trials-will-give-the-uk-92534653bc5d2139Pharma Surgeen2026-07-01T12:29:47.000ZUnlocking NHS data to increase recruitment into clinical trials will give the UK a competitive edge, says ABPIhttps://www.pharmaradar360.com/article/life-sciences-sector-policy-delivery-68429ca6fdb6c8c7Pharma Surgeen2026-07-01T12:29:47.000ZLife Sciences Sector Policy Deliveryhttps://www.pharmaradar360.com/article/abpi-response-to-publication-of-england-s-rare-diseases-action-plan-2026-1893ae34a1dad84dPharma Surgeen2026-07-01T12:29:47.000ZABPI response to publication of England's Rare Diseases Action Plan 2026https://www.pharmaradar360.com/article/abpi-response-to-national-cancer-plan-f590be0aea10d346Pharma Surgeen2026-07-01T12:29:43.000ZABPI response to National Cancer Planhttps://www.pharmaradar360.com/article/abpi-comment-on-measles-outbreak-and-childhood-vaccination-0554ac809ee63790Pharma Surgeen2026-07-01T12:29:43.000ZABPI comment on measles outbreak and childhood vaccinationhttps://www.pharmaradar360.com/article/the-uk-should-seek-to-be-a-european-leader-for-rare-disease-medicine-says-new-re-caf0bfd881490b33Pharma Surgeen2026-07-01T12:29:43.000ZThe UK should seek to be a European leader for rare disease medicine, says new reporthttps://www.pharmaradar360.com/article/abpi-celebrates-a-month-of-major-investment-commitments-into-uk-life-sciences-2aa5a02f8c885674Pharma Surgeen2026-07-01T12:29:43.000ZABPI celebrates a month of major investment commitments into UK life scienceshttps://www.pharmaradar360.com/article/uk-tumbles-down-global-rankings-for-pharma-investment-and-research-0343d3b8ae14b440Pharma Surgeen2026-07-01T12:29:42.000ZUK tumbles down global rankings for pharma investment and researchhttps://www.pharmaradar360.com/article/the-uk-risks-undervaluing-life-sciences-manufacturing-investment-56a23fbf03e7ed1cPharma Surgeen2026-07-01T12:29:42.000ZThe UK risks undervaluing life sciences manufacturing investmenthttps://www.pharmaradar360.com/article/companies-granted-extension-to-vpag-2026-decision-deadline-97964c098c6bf889Pharma Surgeen2026-07-01T12:29:42.000ZCompanies granted extension to VPAG 2026 decision deadlinehttps://www.pharmaradar360.com/article/abpi-launches-manifesto-to-make-scotland-a-leader-in-r-d-and-cutting-edge-medici-e5abfa135e10b476Pharma Surgeen2026-07-01T12:29:41.000ZABPI launches manifesto to make Scotland a leader in R&D and cutting-edge medicineshttps://www.pharmaradar360.com/article/companies-granted-further-extension-to-vpag-2026-decision-deadline-267fe49733755de7Pharma Surgeen2026-07-01T12:29:41.000ZCompanies granted further extension to VPAG 2026 decision deadlinehttps://www.pharmaradar360.com/article/scotland-s-life-sciences-strategy-is-a-welcome-vision-that-must-be-matched-with-6f1fb59c5fd6428cPharma Surgeen2026-07-01T12:29:41.000ZScotland's life sciences strategy is a welcome vision that must be matched with delivery, says ABPIhttps://www.pharmaradar360.com/article/new-external-member-of-university-council-8ce90bb6e3a51834Pharma Surgeen2026-07-01T12:22:16.000ZNew External Member of University Councilhttps://www.pharmaradar360.com/article/reliability-determines-success-in-the-biotech-industry-593cf57750fe86cePharma Surgeen2026-07-01T12:16:17.000ZReliability Determines Success in the Biotech Industryhttps://www.pharmaradar360.com/article/quantum-a-risk-worth-taking-1d34c1f470a6840ePharma Surgeen2026-07-01T12:07:24.000ZQuantum: A risk worth takinghttps://www.pharmaradar360.com/article/ipsen-gets-the-memo-penning-700m-deal-to-buy-rare-disease-biotech-for-clinical-s-069357c690ca23aaPharma Surgeen2026-07-01T12:05:39.000ZIpsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage assethttps://www.pharmaradar360.com/article/tavneos-recall-pressure-mounts-as-eu-joins-fda-seeking-market-removal-9cd89ac8e341a711Pharma Surgeen2026-07-01T12:00:00.000ZTavneos Recall Pressure Mounts, As EU Joins FDA Seeking Market Removalhttps://www.pharmaradar360.com/article/escuela-de-invierno-2026-a-50-anos-del-golpe-civico-militar-106dcd4c1dcdbe79Pharma Surgeen2026-07-01T11:59:47.000ZEscuela de Invierno 2026 – A 50 años del golpe cívico-militarhttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-01T11:59:25.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/vaccine-update-issue-372-june-2026-menb-special-60599e6b4e31904aPharma Surgeen2026-07-01T11:59:00.000ZVaccine update: issue 372, June 2026, MenB specialhttps://www.pharmaradar360.com/article/fda-approves-orca-bio-s-t-cell-therapy-for-blood-cancer-patients-da86d1a31fc39d1fPharma Surgeen2026-07-01T11:40:34.000ZFDA approves Orca Bio’s T cell therapy for blood cancer patientshttps://www.pharmaradar360.com/article/harpreet-singh-supporting-biotech-through-clinical-and-regulatory-strategy-83aed7325848f90cPharma Surgeen2026-07-01T11:31:44.000ZHarpreet Singh: Supporting Biotech Through Clinical and Regulatory Strategyhttps://www.pharmaradar360.com/article/while-you-watched-chips-biotech-nearly-doubled-here-s-why-d6cece50a9f35a8aPharma Surgeen2026-07-01T11:30:33.000ZWhile You Watched Chips, Biotech Nearly Doubled — Here's Whyhttps://www.pharmaradar360.com/article/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listin-5e9441f806996141Pharma Surgeen2026-07-01T11:30:00.000ZAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)https://www.pharmaradar360.com/article/new-medical-devices-and-appliances-database-emddb-launches-next-week-20a3c512317e4165Pharma Surgeen2026-07-01T11:24:01.000ZNew Medical Devices and Appliances Database (EMDDB) launches next weekhttps://www.pharmaradar360.com/article/circle-u-universite-paris-cite-is-recruiting-for-its-new-democracy-chair-de1bad9a83576c23Pharma Surgeen2026-07-01T11:16:02.000ZCircle U.: Université Paris Cité is recruiting for its new ‘Democracy’ chairhttps://www.pharmaradar360.com/article/medical-journal-retracts-tavneos-pivotal-paper-amid-wider-regulatory-clampdown-488ee88452b0e749Pharma Surgeen2026-07-01T11:07:48.000ZMedical journal retracts Tavneos pivotal paper amid wider regulatory clampdownhttps://www.pharmaradar360.com/article/prac-juni-2026-herziening-afgerond-van-veiligheidssignaal-over-valproaat-en-verw-9c15f77ecd083172Pharma Surgeen2026-07-01T11:06:59.000ZPRAC juni 2026: herziening afgerond van veiligheidssignaal over valproaat en verwante stoffen en aanbeveling voor gezondheidszorgbeoefenaars met nieuwe veiligheidsgegevens over chikungunya-vaccin Ixchiqhttps://www.pharmaradar360.com/article/sompo-c465f6e6bb9e5003Pharma Surgeen2026-07-01T11:00:00.000Z「SOMPOサステナビリティ・インデックス」の構成銘柄に選定https://www.pharmaradar360.com/article/inverclyde-public-holiday-reminder-e98fb11105e32977Pharma Surgeen2026-07-01T10:50:02.000ZInverclyde public holiday reminderhttps://www.pharmaradar360.com/article/kemri-and-aref-explore-expanded-collaboration-to-strengthen-research-capacity-in-eb50338965ccb97ePharma Surgeen2026-07-01T10:36:27.000ZKEMRI and AREF Explore Expanded Collaboration to Strengthen Research Capacity in Africahttps://www.pharmaradar360.com/article/lonza-expands-manufacturing-capacity-for-hpapi-and-adc-payload-linkers-9f08463e6065aebdPharma Surgeen2026-07-01T10:34:30.000ZLonza expands manufacturing capacity for HPAPI and ADC payload-linkershttps://www.pharmaradar360.com/article/new-transatlantic-research-network-athena-advances-mechanistic-insights-and-tran-61bb4e4f270fad00Pharma Surgeen2026-07-01T10:20:42.000ZNew transatlantic research network ATHENA advances mechanistic insights and translational applications in cardiovascular diseasehttps://www.pharmaradar360.com/article/prof-mesias-alfeus-s-vision-brings-global-finance-congress-to-africa-9e6ee115bd5ab49bPharma Surgeen2026-07-01T10:19:03.000ZProf Mesias Alfeus’s vision brings global finance congress to Africahttps://www.pharmaradar360.com/article/telum-raises-18-million-euros-for-hospital-pneumonia-program-6ca41f650918e4c2Pharma Surgeen2026-07-01T10:15:07.000ZTelum raises 18 million euros for hospital pneumonia programhttps://www.pharmaradar360.com/article/alzecure-lands-2-2-billion-neurorestore-licensing-deal-72c21c4570dad3dcPharma Surgeen2026-07-01T10:15:07.000ZAlzeCure lands $2.2 billion NeuroRestore licensing dealhttps://www.pharmaradar360.com/article/kemri-takes-centre-stage-as-act-chik-project-kicks-off-to-advance-chikungunya-va-09d8bf5508af2f0bPharma Surgeen2026-07-01T10:13:16.000ZKEMRI Takes Centre Stage as ACT-CHIK Project Kicks Off to Advance Chikungunya Vaccine Research in Africahttps://www.pharmaradar360.com/article/new-drug-data-makes-this-french-biotech-stock-a-buy-says-jefferies-1dc8dc0b61b6a13bPharma Surgeen2026-07-01T10:12:10.000ZNew drug data makes this French biotech stock a buy, says Jefferieshttps://www.pharmaradar360.com/article/lilly-and-regeneron-amongst-first-incumbents-to-fda-s-fast-track-facility-scheme-adf9737b74e87ef3Pharma Surgeen2026-07-01T10:09:45.000ZLilly and Regeneron amongst first incumbents to FDA’s fast-track facility schemehttps://www.pharmaradar360.com/article/goldenwell-biotech-gwll-q1-2026-shows-loss-and-going-concern-warning-df74ecaf53929bfcPharma Surgeen2026-07-01T10:09:20.000ZGoldenwell Biotech (GWLL) Q1 2026 shows loss and going concern warninghttps://www.pharmaradar360.com/article/goldenwell-biotech-otcqb-gwll-flags-going-concern-risk-in-2025-cf13ce25a3877f74Pharma Surgeen2026-07-01T10:09:20.000ZGoldenwell Biotech (OTCQB: GWLL) flags going concern risk in 2025https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-is-up-6-7-after-21-revenue-jump-on-injectable-d-47cc861d6fc42d91Pharma Surgeen2026-07-01T10:08:19.000ZWest Pharmaceutical Services (WST) Is Up 6.7% After 21% Revenue Jump On Injectable Demand - Has The Bull Case Changed?https://www.pharmaradar360.com/article/centogene-apac-office-official-opening-ceremony-in-taiwan-5e7c2f33ff3d28adPharma Surgeen2026-07-01T10:07:11.000ZCENTOGENE APAC Office Official Opening Ceremony in Taiwanhttps://www.pharmaradar360.com/article/act-brief-tavneos-trial-integrity-issues-selective-safety-data-regulatory-pathwa-d14bf0a3f9a7f024Pharma Surgeen2026-07-01T10:06:40.000ZACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launchhttps://www.pharmaradar360.com/article/goldenwell-biotech-inc-fy-2025-revenue-55-net-loss-296471-eps-2-99-10-k-summary-ea57dfc53f124f66Pharma Surgeen2026-07-01T10:05:01.000ZGOLDENWELL BIOTECH, INC. FY 2025: Revenue $55 Net loss $296471 EPS $(2.99) — 10-K Summaryhttps://www.pharmaradar360.com/article/goldenwell-biotech-inc-1q-2026-revenue-0-eps-0-00018-10-q-summary-71268ca281a05e1bPharma Surgeen2026-07-01T10:01:01.000ZGOLDENWELL BIOTECH, INC. 1Q 2026: Revenue $0 EPS $(0.00018) — 10-Q Summaryhttps://www.pharmaradar360.com/article/how-a-chinese-heart-could-get-us-blood-pumping-despite-biotech-decoupling-801466b4a21cfe26Pharma Surgeen2026-07-01T10:00:11.000ZHow a ‘Chinese heart’ could get US blood pumping despite biotech decouplinghttps://www.pharmaradar360.com/article/lab-created-spudcell-marks-stunning-step-toward-building-life-from-scratch-9966f2435db7f991Pharma Surgeen2026-07-01T10:00:00.000ZLab-created ‘SpudCell’ marks ‘stunning’ step toward building life from scratchhttps://www.pharmaradar360.com/article/abivax-expands-obefazimod-safety-data-ahead-of-fda-filing-57029d6faeceac41Pharma Surgeen2026-07-01T09:59:59.000ZAbivax expands obefazimod safety data ahead of FDA filinghttps://www.pharmaradar360.com/article/kapihan-session-convenes-media-and-biotech-experts-for-a-dialogue-on-agricultura-377588e82dc66952Pharma Surgeen2026-07-01T09:53:43.000ZKapihan Session Convenes Media and Biotech Experts for a Dialogue on Agricultural Biotechnologyhttps://www.pharmaradar360.com/article/4708-cabdf63b6a2f0e25Pharma Surgeen2026-07-01T09:37:59.000Z4708https://www.pharmaradar360.com/article/4707-8003cbbb2de7d330Pharma Surgeen2026-07-01T09:36:44.000Z4707https://www.pharmaradar360.com/article/europe-s-best-ai-literacy-initiative-for-education-comes-from-finland-cc45e34c3ae40328Pharma Surgeen2026-07-01T09:34:42.000ZEurope’s best AI literacy initiative for education comes from Finlandhttps://www.pharmaradar360.com/article/4706-4c09c5bdd99442bcPharma Surgeen2026-07-01T09:34:38.000Z4706https://www.pharmaradar360.com/article/the-quiet-winner-behind-the-ai-trade-biotech-s-2026-comeback-a723f4aa062804f0Pharma Surgeen2026-07-01T09:34:14.000ZThe Quiet Winner Behind the AI Trade: Biotech’s 2026 Comebackhttps://www.pharmaradar360.com/article/sicherung-des-erfahrungswissens-in-der-pflege-94aa1750c95dd382Pharma Surgeen2026-07-01T09:32:47.000ZSicherung des Erfahrungswissens in der Pflegehttps://www.pharmaradar360.com/article/cough-cold-877c2faa981b330bPharma Surgeen2026-07-01T09:25:44.000ZCough & coldhttps://www.pharmaradar360.com/article/pain-management-74e41bd83ec19eadPharma Surgeen2026-07-01T09:25:44.000ZPain managementhttps://www.pharmaradar360.com/article/neurology-a58b635c9e0a6948Pharma Surgeen2026-07-01T09:25:44.000ZNeurologyhttps://www.pharmaradar360.com/article/cardiometabolic-71013c17e503dc1fPharma Surgeen2026-07-01T09:25:44.000ZCardiometabolichttps://www.pharmaradar360.com/article/intim-health-eca7c77944742754Pharma Surgeen2026-07-01T09:25:44.000ZIntim healthhttps://www.pharmaradar360.com/article/gastroenterology-7cd4a508c75ee48ePharma Surgeen2026-07-01T09:25:44.000ZGastroenterologyhttps://www.pharmaradar360.com/article/skin-care-9aa94a454f51adf8Pharma Surgeen2026-07-01T09:25:44.000ZSkin carehttps://www.pharmaradar360.com/article/antibiotics-and-antiseptics-fa9bdda42fd922adPharma Surgeen2026-07-01T09:25:44.000ZAntibiotics and antisepticshttps://www.pharmaradar360.com/article/drugs-for-allergy-59a97128d8db45f3Pharma Surgeen2026-07-01T09:25:44.000ZDrugs for Allergyhttps://www.pharmaradar360.com/article/a86aeaacc0794fc2Pharma Surgeen2026-07-01T09:25:44.000ZПрепарати від застуди та температуриhttps://www.pharmaradar360.com/article/67fd799badde67b2Pharma Surgeen2026-07-01T09:25:44.000ZПрепарати від болю та запаленняhttps://www.pharmaradar360.com/article/7e50fbf1abda0ef5Pharma Surgeen2026-07-01T09:25:44.000ZНеврологічні препаратиhttps://www.pharmaradar360.com/article/711130ed8801dad3Pharma Surgeen2026-07-01T09:25:44.000ZКардіометаболічні препаратиhttps://www.pharmaradar360.com/article/093eccbbf126368dPharma Surgeen2026-07-01T09:25:44.000ZПрепарати для інтимного здоров'яhttps://www.pharmaradar360.com/article/4b0e5cd187e5d81bPharma Surgeen2026-07-01T09:25:44.000ZПрепарати для застосування у хірургіїhttps://www.pharmaradar360.com/article/936f09610928a995Pharma Surgeen2026-07-01T09:25:44.000ZГастроентерологічні препаратиhttps://www.pharmaradar360.com/article/a7acf071e3e232d9Pharma Surgeen2026-07-01T09:25:44.000ZДерматологічні препаратиhttps://www.pharmaradar360.com/article/5daddcfeb2c6c35aPharma Surgeen2026-07-01T09:25:44.000ZАнтибактеріальні препарати та антисептикиhttps://www.pharmaradar360.com/article/f8dbae610e164eebPharma Surgeen2026-07-01T09:25:44.000ZПрепарати при алергіїhttps://www.pharmaradar360.com/article/d3127f1a42d5f338Pharma Surgeen2026-07-01T09:25:44.000ZПрепаратиhttps://www.pharmaradar360.com/article/radiopharmaceutical-trials-an-operational-playbook-12fd30599c3e9f34Pharma Surgeen2026-07-01T09:25:04.000ZRadiopharmaceutical Trials: An Operational Playbookhttps://www.pharmaradar360.com/article/roderic-guigo-elected-to-the-embo-membership-56456b020e5b6af4Pharma Surgeen2026-07-01T09:21:14.000ZRoderic Guigó elected to the EMBO Membershiphttps://www.pharmaradar360.com/article/tutors-help-new-students-settle-into-their-new-environment-20eef4901c02eef6Pharma Surgeen2026-07-01T09:16:24.000ZTutors help new students settle into their new environmenthttps://www.pharmaradar360.com/article/national-chlamydia-screening-programme-ncsp-incident-reporting-policy-0672a64ca91c74c7Pharma Surgeen2026-07-01T09:15:55.000ZNational Chlamydia Screening Programme (NCSP): incident reporting policyhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-china-resources-pharmaceutical-group-ltd-hkex-3320-b0fd53eeffb32e34Pharma Surgeen2026-07-01T09:09:54.000ZPrice to earnings forward of China Resources Pharmaceutical Group Ltd. – HKEX:3320https://www.pharmaradar360.com/article/primare-hirntumoren-und-hirnmetastasen-neue-behandlungsansatze-85e14ef9b1b5131ePharma Surgeen2026-07-01T09:00:02.000ZPrimäre Hirntumoren und Hirnmetastasen: neue Behandlungsansätzehttps://www.pharmaradar360.com/article/can-glp-1-medications-improve-health-in-people-with-type-2-diabetes-and-pad-c7da23592ae37da3Pharma Surgeen2026-07-01T09:00:00.000ZCan GLP-1 medications improve health in people with Type 2 diabetes and PAD?https://www.pharmaradar360.com/article/beyond-the-glp-1ra-weight-loss-ceiling-bfdcd2789ab0565cPharma Surgeen2026-07-01T08:59:44.000ZBeyond the GLP-1RA weight loss ceilinghttps://www.pharmaradar360.com/article/massachusetts-biotech-layoffs-drop-to-lowest-level-in-over-two-years-3306c415e957eeecPharma Surgeen2026-07-01T08:50:00.000ZMassachusetts biotech layoffs drop to lowest level in over two yearshttps://www.pharmaradar360.com/article/tracking-cathie-wood-doubling-down-on-ai-biotech-and-crypto-retreating-from-geno-648a1d977138792fPharma Surgeen2026-07-01T08:41:21.000ZTracking Cathie Wood: Doubling Down on AI-Biotech and Crypto, Retreating From Genomics and China Techhttps://www.pharmaradar360.com/article/backed-by-top-vcs-biotech-bags-alzheimer-s-med-in-2-2b-deal-a939ff27f66cd618Pharma Surgeen2026-07-01T08:40:40.000ZBacked by top VCs, biotech bags Alzheimer’s med in $2.2B dealhttps://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-monthly-data-2025-to-2026-46183ecdfec674ccPharma Surgeen2026-07-01T08:30:01.000ZMRSA, MSSA, Gram-negative bacteraemia and CDI: monthly data, 2025 to 2026https://www.pharmaradar360.com/article/rsv-vaccination-expansion-of-eligibility-to-older-adults-in-certain-clinical-ris-35805c2e55b3981ePharma Surgeen2026-07-01T08:30:01.000ZRSV vaccination: expansion of eligibility to older adults in certain clinical risk groupshttps://www.pharmaradar360.com/article/pre-release-access-list-monthly-hcai-statistical-release-be74553657c78f7ePharma Surgeen2026-07-01T08:30:01.000ZPre-release access list: monthly HCAI statistical releasehttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-programme-7a9417a4fdf76e56Pharma Surgeen2026-07-01T08:30:01.000ZRespiratory syncytial virus (RSV) vaccination programmehttps://www.pharmaradar360.com/article/national-child-measurement-programme-operational-guidance-80a05d8f25e9c2b6Pharma Surgeen2026-07-01T08:30:00.000ZNational Child Measurement Programme: operational guidancehttps://www.pharmaradar360.com/article/national-child-measurement-programme-information-for-schools-aa4c279f547ed2b3Pharma Surgeen2026-07-01T08:30:00.000ZNational Child Measurement Programme: information for schoolshttps://www.pharmaradar360.com/article/ipsen-acquires-swiss-based-memo-therapeutics-501da5fb34e21753Pharma Surgeen2026-07-01T08:22:03.000ZIpsen acquires Swiss-based Memo Therapeuticshttps://www.pharmaradar360.com/article/chellaram-foundation-5-million-gift-to-oxford-launches-new-programme-for-healthy-36ccdd45a2f01002Pharma Surgeen2026-07-01T08:13:00.000ZChellaram Foundation £5 million gift to Oxford launches new programme for healthy and sustainable dietshttps://www.pharmaradar360.com/article/oncologia-neurologia-infezioni-e-malattie-infiammatorie-al-policlinico-di-milano-4514604907a79162Pharma Surgeen2026-07-01T08:07:00.000ZOncologia, neurologia, infezioni e malattie infiammatorie: al Policlinico di Milano fabbrica hi-tech e radiofarmaci “in casa” per diagnosi rapide e cure personalizzatehttps://www.pharmaradar360.com/article/proposed-new-satellite-fleets-could-overwhelm-the-night-sky-239bf452d5eed37dPharma Surgeen2026-07-01T08:00:00.000ZProposed new satellite fleets could overwhelm the night skyhttps://www.pharmaradar360.com/article/fda-seizes-adulterated-milk-dairy-products-and-sweets-worth-rs-13-71-lakh-2b04f2be00ce4925Pharma Surgeen2026-07-01T07:52:00.000ZFDA seizes adulterated milk, dairy products and sweets worth Rs 13.71 lakhhttps://www.pharmaradar360.com/article/hims-stock-slips-overnight-after-fda-staff-questions-safety-of-popular-peptides-9797db907d251b54Pharma Surgeen2026-07-01T07:14:55.000ZHIMS Stock Slips Overnight After FDA Staff Questions Safety Of Popular Peptides — But One Analyst Says ‘This Isn’t The End’https://www.pharmaradar360.com/article/imcd-opens-new-pharmaceutical-technical-centre-in-new-jersey-b80ea61c71e7a7eaPharma Surgeen2026-07-01T07:04:13.000ZIMCD opens new Pharmaceutical Technical Centre in New Jerseyhttps://www.pharmaradar360.com/article/golden-triangle-still-dominates-but-talent-and-capital-gaps-slow-biotech-growth-a53aa7d1cf5ae9abPharma Surgeen2026-07-01T07:01:33.000ZGolden Triangle still dominates, but talent and capital gaps slow biotech growthhttps://www.pharmaradar360.com/article/a-desire-to-make-a-difference-dr-davies-becomes-unmc-chancellor-f9cfe8c356910703Pharma Surgeen2026-07-01T07:00:00.000ZA desire to make a difference: Dr. Davies becomes UNMC chancellorhttps://www.pharmaradar360.com/article/several-open-access-publishing-agreements-approach-their-cap-bddc2dea2fff1fd1Pharma Surgeen2026-07-01T07:00:00.000ZSeveral Open Access publishing agreements approach their caphttps://www.pharmaradar360.com/article/fourth-of-july-fireworks-can-cause-serious-eye-injuries-doctor-warns-2165ca8d490cb668Pharma Surgeen2026-07-01T07:00:00.000ZFourth of July fireworks can cause serious eye injuries, doctor warnshttps://www.pharmaradar360.com/article/causal-machine-learning-guided-personalized-immunochemotherapy-strategies-in-int-e07cee315f28a857Pharma Surgeen2026-07-01T07:00:00.000ZCausal machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma (CMICC).https://www.pharmaradar360.com/article/an-integrative-multi-omics-machine-learning-framework-for-precision-metastasis-p-f0c26e3f1bf0d334Pharma Surgeen2026-07-01T07:00:00.000ZAn integrative multi-omics machine learning framework for precision metastasis prediction and clinical staging in non-small cell lung cancer.https://www.pharmaradar360.com/article/the-pan-sur-in-score-for-advanced-pancreatic-cancer-a-comprehensive-analysis-of-b10eb563897a0a31Pharma Surgeen2026-07-01T07:00:00.000ZThe PAN-SUR(IN) score for advanced pancreatic cancer: A comprehensive analysis of methodology, prognostic derivation, and clinical risk stratification.https://www.pharmaradar360.com/article/germline-testing-in-pancreatic-adenocarcinoma-a-retrospective-cohort-study-of-ge-12cb1dfba144ba07Pharma Surgeen2026-07-01T07:00:00.000ZGermline testing in pancreatic adenocarcinoma: A retrospective cohort study of germline genetic testing uptake, patterns of referral, clinical findings and impact in the South Western Sydney Local Health District.https://www.pharmaradar360.com/article/surgical-outcomes-and-recurrence-risk-factors-for-rectal-gastrointestinal-stroma-4e5f65ce9f8c2555Pharma Surgeen2026-07-01T07:00:00.000ZSurgical outcomes and recurrence risk factors for rectal gastrointestinal stromal tumors: A comparison of transabdominal and transanal resection.https://www.pharmaradar360.com/article/efficacy-and-safety-of-first-line-pd-1-pd-l1-inhibitor-based-therapy-in-esophage-9d69236d21c4a3f2Pharma Surgeen2026-07-01T07:00:00.000ZEfficacy and safety of first-line PD-1/PD-L1 inhibitor–based therapy in esophageal squamous cell carcinoma: A systematic review and meta-analysis.https://www.pharmaradar360.com/article/nodal-status-guided-postoperative-radiotherapy-after-neoadjuvant-chemoimmunother-923bd8032c10099aPharma Surgeen2026-07-01T07:00:00.000ZNodal status–guided postoperative radiotherapy after neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter cohort study.https://www.pharmaradar360.com/article/a-gan-based-multimodal-framework-for-preoperative-response-prediction-in-her2-ne-a938c97bc3dff159Pharma Surgeen2026-07-01T07:00:00.000ZA GAN-based multimodal framework for preoperative response prediction in HER2-negative locally advanced gastric cancer treated with neoadjuvant chemoimmunotherapy.https://www.pharmaradar360.com/article/neoadjuvant-chemotherapy-plus-serplulimab-and-immuno-response-molecular-subtype-468cf9db378240e7Pharma Surgeen2026-07-01T07:00:00.000ZNeoadjuvant chemotherapy plus serplulimab and immuno-response molecular subtype for pMMR locally advanced rectal cancer (FIRM).https://www.pharmaradar360.com/article/transformer-based-multi-omics-synthesis-for-early-risk-stratification-and-preven-811d0694e15987f6Pharma Surgeen2026-07-01T07:00:00.000ZTransformer-based multi-omics synthesis for early risk stratification and preventive surveillance in liver oncology.https://www.pharmaradar360.com/article/pathological-complete-response-after-neoadjuvant-chemoimmunotherapy-with-toripal-9bf56415c107f3d0Pharma Surgeen2026-07-01T07:00:00.000ZPathological complete response after neoadjuvant chemoimmunotherapy with toripalimab or camrelizumab in esophageal squamous cell carcinoma: A systematic review and meta-analysis.https://www.pharmaradar360.com/article/hepatic-arterial-infusion-chemotherapy-plus-immune-checkpoint-inhibitors-and-len-3154f847c04f1409Pharma Surgeen2026-07-01T07:00:00.000ZHepatic arterial infusion chemotherapy plus immune checkpoint inhibitors and lenvatinib for locally advanced biliary tract cancer: A single-arm, exploratory study.https://www.pharmaradar360.com/article/adebrelimab-plus-interventional-and-targeted-therapy-for-unresectable-hepatocell-bf49a7f692682f35Pharma Surgeen2026-07-01T07:00:00.000ZAdebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: A single-arm, real-world study.https://www.pharmaradar360.com/article/neoadjuvant-anti-pd-1-monotherapy-in-msi-h-locally-advanced-gastric-cancer-3-yea-b2da7b3f63a1226bPharma Surgeen2026-07-01T07:00:00.000ZNeoadjuvant anti-PD-1 monotherapy in MSI-H locally advanced gastric cancer: 3-Year survival without surgery.https://www.pharmaradar360.com/article/relb-ilf2-gm-csf-loop-to-sustain-mdsc-mediated-prostate-cancer-immunosuppression-a8621ede2c828cc1Pharma Surgeen2026-07-01T07:00:00.000ZRelB/ILF2–GM-CSF loop to sustain MDSC-mediated prostate cancer immunosuppression.https://www.pharmaradar360.com/article/endoscopic-submucosal-dissection-for-early-gastrointestinal-neoplasms-a-prospect-e4d90bb182e6bc07Pharma Surgeen2026-07-01T07:00:00.000ZEndoscopic submucosal dissection for early gastrointestinal neoplasms: A prospective study of 50 cases in 45 patients in Vietnam.https://www.pharmaradar360.com/article/circulating-tumor-suppressor-micrornas-as-minimally-invasive-biomarkers-for-earl-6afb151f24bf95c0Pharma Surgeen2026-07-01T07:00:00.000ZCirculating tumor suppressor microRNAs as minimally invasive biomarkers for early detection of colorectal cancer.https://www.pharmaradar360.com/article/addressing-radiologist-inter-reader-variability-in-gastric-cancer-t-staging-a-pr-efbfbef113a7164aPharma Surgeen2026-07-01T07:00:00.000ZAddressing radiologist inter-reader variability in gastric cancer T staging: A prospective study using the dual-module AI model, TRACE.https://www.pharmaradar360.com/article/68ga-nodaga-sna009-a-first-in-class-single-domain-antibody-probe-for-rapid-pet-i-4f909e0e3885afd5Pharma Surgeen2026-07-01T07:00:00.000Z68Ga-NODAGA-SNA009: A first-in-class single-domain antibody probe for rapid PET imaging of GPA33 in colorectal cancer.https://www.pharmaradar360.com/article/liposomal-irinotecan-hr070803-plus-fluorouracil-and-bevacizumab-as-second-line-t-b455f1f72e55aa43Pharma Surgeen2026-07-01T07:00:00.000ZLiposomal irinotecan (HR070803) plus fluorouracil and bevacizumab as second-line treatment in advanced colorectal cancer: Cohort A results from a phase 2 trial.https://www.pharmaradar360.com/article/family-discovers-crucial-information-through-genetic-insights-project-34c2dce6d1b7bbd6Pharma Surgeen2026-07-01T06:58:00.000ZFamily discovers crucial information through Genetic Insights Projecthttps://www.pharmaradar360.com/article/submissions-for-healing-arts-staff-exhibition-due-july-31-6969fa3572ed3d26Pharma Surgeen2026-07-01T06:56:00.000ZSubmissions for Healing Arts staff exhibition due July 31https://www.pharmaradar360.com/article/unsicher-bei-der-hpv-impfung-2e1c02affd8979b4Pharma Surgeen2026-07-01T06:45:57.000ZUnsicher bei der HPV-Impfung?https://www.pharmaradar360.com/article/pole-dentaire-des-hus-l-expertise-des-chirurgien-dentistes-des-hus-au-service-de-612bb6989792b7baPharma Surgeen2026-07-01T06:30:00.000ZPôle dentaire des HUS : l’expertise des chirurgien dentistes des HUS au service des patients âgéshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-opens-south-san-francisco-research-hub-to-facilitate-acade-3832bcb391aee635Pharma Surgeen2026-07-01T06:07:52.000ZChugai Pharmaceutical Opens South San Francisco Research Hub to Facilitate Academic Collaborationshttps://www.pharmaradar360.com/article/9-4-ab3ad7fbfaa51da3Pharma Surgeen2026-07-01T06:00:41.000Z厚生労働省臨床研究総合促進事業 監査担当者養成研修ー初級編ー開催のお知らせ(9/4開催)https://www.pharmaradar360.com/article/vgr-s-budget-for-2027-tydligare-krav-pa-resultat-b721095f28ca3fa2Pharma Surgeen2026-07-01T06:00:16.000ZVGR:s budget för 2027: tydligare krav på resultathttps://www.pharmaradar360.com/article/keti-koti-2026-commemorating-and-celebrating-334f783a3f5fa41bPharma Surgeen2026-07-01T05:58:19.000ZKeti Koti 2026: commemorating and celebratinghttps://www.pharmaradar360.com/article/ipsen-to-buy-swiss-biotech-memo-in-deal-that-could-top-800-million-73876289c22bac33Pharma Surgeen2026-07-01T05:55:00.000ZIpsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Millionhttps://www.pharmaradar360.com/article/nicox-s-ncx-470-new-drug-application-submitted-in-the-united-states-by-kowa-with-594db60965f7b910Pharma Surgeen2026-07-01T05:40:24.000ZNicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Paymenthttps://www.pharmaradar360.com/article/axsome-advances-solriamfetol-into-phase-3-trial-in-adolescent-adhd-as-first-pati-1404e47e0e837325Pharma Surgeen2026-07-01T05:21:24.000ZAxsome advances solriamfetol into Phase 3 trial in adolescent ADHD as first patient is dosedhttps://www.pharmaradar360.com/article/french-biotech-ipsen-to-buy-memo-therapeutics-for-230-million-upfront-6da978da538b6a1cPharma Surgeen2026-07-01T05:17:00.000ZFrench biotech Ipsen to buy Memo Therapeutics for $230 million upfronthttps://www.pharmaradar360.com/article/new-haven-biotech-company-developing-measles-treatment-as-us-cases-top-2-100-847db1483fa2587ePharma Surgeen2026-07-01T05:15:05.000ZNew Haven biotech company developing measles treatment as US cases top 2,100https://www.pharmaradar360.com/article/kirsten-detrick-a-connective-tissue-across-biotech-692a028db0e2880aPharma Surgeen2026-07-01T05:02:51.000ZKirsten Detrick: A connective tissue across biotechhttps://www.pharmaradar360.com/article/eucope-strengthens-its-expertise-on-joint-clinical-assessments-with-the-appointm-677515b55345a241Pharma Surgeen2026-07-01T05:00:33.000ZEUCOPE strengthens its expertise on Joint Clinical Assessments with the appointment of Dr. Thomas Eckerhttps://www.pharmaradar360.com/article/ways-to-reduce-legionella-risk-0d337c650a9a92c9Pharma Surgeen2026-07-01T04:56:59.000ZWays to reduce Legionella riskhttps://www.pharmaradar360.com/article/trinity-biotech-s-trinovium-secures-open-compute-project-membership-advancing-hy-4542b73f25657fd4Pharma Surgeen2026-07-01T04:24:03.000ZTrinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Coolinghttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-fujichenon-2c46eb29a72448a1Pharma Surgeen2026-07-01T03:00:00.000Z[SHINSA]English Translation of Review Report: Fujichenonhttps://www.pharmaradar360.com/article/shinsa-software-as-a-medical-device-samd-page-updated-7fd97df80e5d58f5Pharma Surgeen2026-07-01T03:00:00.000Z[SHINSA]Software as a Medical Device (SaMD) page updatedhttps://www.pharmaradar360.com/article/amed-8-3-7-22-9b702660cae90405Pharma Surgeen2026-07-01T02:59:59.000Z【AMED】令和8年度「革新的がん医療実用化研究事業」に係る公募（3次公募）のご案内［7月22日（水）正午締切］https://www.pharmaradar360.com/article/aribio-independently-completes-global-phase-3-trial-of-oral-alzheimer-s-drug-can-3f044d99763bdb8aPharma Surgeen2026-07-01T02:15:16.000ZAriBio Independently Completes Global Phase 3 Trial of Oral Alzheimer's Drug Candidate 'AR1001'https://www.pharmaradar360.com/article/menicon-group-strengthens-its-sales-foundation-in-eastern-japan-and-creates-new-96ceecc63adbddbbPharma Surgeen2026-07-01T01:00:00.000Z- Menicon Group strengthens its sales foundation in eastern Japan and creates new customer touchpoints -Announcement of stock acquisition of Inter-Optical Co., Ltd.https://www.pharmaradar360.com/article/shoko-co-ltd-began-commercial-production-of-pharmaceutical-excipient-viscomedi-a-73a8d5aeb77ebe90Pharma Surgeen2026-07-01T01:00:00.000ZShoko Co., Ltd. Began Commercial Production of Pharmaceutical Excipient “Viscomedi” at Its South Korean Planthttps://www.pharmaradar360.com/article/abvx-stock-clocks-best-day-in-11-months-on-analyst-upgrades-after-fresh-data-eas-d46907f9026ac411Pharma Surgeen2026-07-01T00:13:00.000ZABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concernshttps://www.pharmaradar360.com/article/recce-pharmaceuticals-bolsters-cash-position-with-a-3-67-million-tax-refund-ahea-251fd09026122760Pharma Surgeen2026-07-01T00:07:10.000ZRecce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestoneshttps://www.pharmaradar360.com/article/nova-direcao-do-instituto-de-quimica-assume-com-compromisso-de-fortalecer-ensino-89b1a8ac9655b75fPharma Surgeen2026-07-01T00:02:41.000ZNova direção do Instituto de Química assume com compromisso de fortalecer ensino, pesquisa e inovaçãohttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-6bc765b0f3d0f6eaPharma Surgeen2026-07-01T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-ae6212b9f78e6f5cPharma Surgeen2026-07-01T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/sns-565a0852bc6b80d8Pharma Surgeen2026-07-01T00:00:00.000Z当社名をかたるSNSなりすましアカウントに関する注意喚起https://www.pharmaradar360.com/article/2026-ec070bb469b928a1Pharma Surgeen2026-07-01T00:00:00.000Z「健康経営優良法人2026（大規模法人部門）」に認定https://www.pharmaradar360.com/article/s-p-global-sustainability-yearbook-member-2026-279f05c054bd9481Pharma Surgeen2026-07-01T00:00:00.000ZS&P GlobalによるSustainability Yearbook Member 2026に選定https://www.pharmaradar360.com/article/stn1012700-ryjusea-0-25mg-ml-0ed953aba75cf339Pharma Surgeen2026-07-01T00:00:00.000Z近視の進行抑制を目的とする点眼剤STN1012700（Ryjusea 0.25mg/mL点眼液）についてアジア事業地域で初めてとなる販売承認をフィリピンで取得https://www.pharmaradar360.com/article/0-02-0f9a27bb31a9a203Pharma Surgeen2026-07-01T00:00:00.000Z緑内障・高眼圧症治療剤「ロープレッサ®点眼液0.02%」国内における製造販売承認を取得https://www.pharmaradar360.com/article/80557f7187a4005dPharma Surgeen2026-07-01T00:00:00.000Z「ちびまる子ちゃん」と考える、子どもの近視 ― 日常の気づきから“まずは眼科へ”を伝える疾患啓発メッセージを全国に展開 ―https://www.pharmaradar360.com/article/santen-5-183cebec954fb527Pharma Surgeen2026-07-01T00:00:00.000ZSanten中国、5つの緑内障点眼薬について、中国本土における独占的な流通および販売促進に関する契約を締結https://www.pharmaradar360.com/article/0-1-220382c57ff2118aPharma Surgeen2026-07-01T00:00:00.000Z後天性眼瞼下垂治療剤「アップニーク®ミニ点眼液0.1%」発売のお知らせhttps://www.pharmaradar360.com/article/3e2f5afb2998a486Pharma Surgeen2026-07-01T00:00:00.000Z役員人事に関するお知らせhttps://www.pharmaradar360.com/article/8-edee54b10ac969f7Pharma Surgeen2026-07-01T00:00:00.000Z＜花粉症に対する意識調査＞ 花粉症で「パフォーマンスに影響あり」は8割以上 「初期療法（早期治療）」を正しく知っている人の半数以上は「毎年実施」 ～眼科医と気象予報士が解説、花粉飛散期前の対策で春をより快適に～https://www.pharmaradar360.com/article/40-mg-ml-f2e91aca82d2272cPharma Surgeen2026-07-01T00:00:00.000Zアフリベルセプト硝子体内注射用キット40 mg/mL「バイエル」の発売予定についてhttps://www.pharmaradar360.com/article/new-draft-pmos-guideline-recommends-annual-review-and-could-mean-quicker-diagnos-7d655745f0e8ce05Pharma Surgeen2026-07-01T00:00:00.000ZNew draft PMOS guideline recommends annual review and could mean quicker diagnosishttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-01T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/gpnmb-directed-car-t-cell-therapies-for-solid-tumors-3062861e7bc8e60fPharma Surgeen2026-07-01T00:00:00.000ZGPNMB-directed CAR-T cell therapies for solid tumorshttps://www.pharmaradar360.com/article/idh1-mutant-vaccine-in-newly-diagnosed-astrocytoma-final-analysis-of-the-multice-244bbdc0b671bb34Pharma Surgeen2026-07-01T00:00:00.000ZIDH1 -mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trialhttps://www.pharmaradar360.com/article/gpnmb-directed-car-t-cell-therapy-against-mit-tfe-family-fusion-driven-solid-tum-a2ba8a31d3f9d6f2Pharma Surgeen2026-07-01T00:00:00.000ZGPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumorshttps://www.pharmaradar360.com/article/just-how-goal-directed-are-hippocampal-theta-sweeps-anyway-b37855d6d2c0dbb5Pharma Surgeen2026-07-01T00:00:00.000ZJust how goal-directed are hippocampal theta sweeps, anyway?https://www.pharmaradar360.com/article/hippocampal-theta-sweeps-indicate-goal-direction-during-navigation-b11cf136bcf3d8c1Pharma Surgeen2026-07-01T00:00:00.000ZHippocampal theta sweeps indicate goal direction during navigationhttps://www.pharmaradar360.com/article/goal-directed-hippocampal-theta-sweeps-during-memory-guided-navigation-a4e197b2ee14c68ePharma Surgeen2026-07-01T00:00:00.000ZGoal-directed hippocampal theta sweeps during memory-guided navigationhttps://www.pharmaradar360.com/article/author-correction-spinal-cord-tau-pathology-induces-tactile-deficits-and-cogniti-a646c1ad1857ca4bPharma Surgeen2026-07-01T00:00:00.000ZAuthor Correction: Spinal cord Tau pathology induces tactile deficits and cognitive impairment in Alzheimer’s disease via dysregulation of CCK neuronshttps://www.pharmaradar360.com/article/biological-aging-might-help-to-explain-the-rising-risk-of-early-onset-cancer-b21b05cdcdd114edPharma Surgeen2026-07-01T00:00:00.000ZBiological aging might help to explain the rising risk of early-onset cancerhttps://www.pharmaradar360.com/article/a-meta-analysis-of-the-long-term-effects-of-antihypertensive-therapy-on-the-risk-e7e08093a49e582fPharma Surgeen2026-07-01T00:00:00.000ZA meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trialshttps://www.pharmaradar360.com/article/blood-based-circular-rnas-for-early-diagnosis-of-alzheimer-s-disease-68505ce9c2e3bb9dPharma Surgeen2026-07-01T00:00:00.000ZBlood-based circular RNAs for early diagnosis of Alzheimer’s diseasehttps://www.pharmaradar360.com/article/innate-immune-responsiveness-predicts-enhanced-cellular-immunity-and-symptomatic-5735ed850a3a066cPharma Surgeen2026-07-01T00:00:00.000ZInnate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infectionhttps://www.pharmaradar360.com/article/a-genome-scale-crispri-perturbation-atlas-of-human-induced-pluripotent-stem-cell-3faf41d96c69e78fPharma Surgeen2026-07-01T00:00:00.000ZA genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cellshttps://www.pharmaradar360.com/article/moderate-volcanic-eruptions-and-extreme-wildfires-humidify-the-stratosphere-219017e6cee6ad37Pharma Surgeen2026-07-01T00:00:00.000ZModerate volcanic eruptions and extreme wildfires humidify the stratospherehttps://www.pharmaradar360.com/article/identification-of-cross-stage-cross-species-malaria-cd8-t-cell-antigens-c9a696fc7595aa86Pharma Surgeen2026-07-01T00:00:00.000ZIdentification of cross-stage, cross-species malaria CD8 + T cell antigenshttps://www.pharmaradar360.com/article/n-4-acetylcytidine-enhances-synthetic-mrna-translation-yield-and-fidelity-66c600adc6c6fd68Pharma Surgeen2026-07-01T00:00:00.000ZN 4 -Acetylcytidine enhances synthetic mRNA translation yield and fidelityhttps://www.pharmaradar360.com/article/heat-triggered-phospholipid-flipping-stabilizes-plasma-membrane-fluidity-de9d93a1a15adb46Pharma Surgeen2026-07-01T00:00:00.000ZHeat-triggered phospholipid flipping stabilizes plasma membrane fluidityhttps://www.pharmaradar360.com/article/isomeric-multi-hydrogen-bonding-enables-blue-perovskite-leds-0899e94fe8e9a53fPharma Surgeen2026-07-01T00:00:00.000ZIsomeric multi-hydrogen-bonding enables blue perovskite LEDshttps://www.pharmaradar360.com/article/backreaction-of-stimulated-hawking-radiation-in-an-optical-analogue-b365d16272934c76Pharma Surgeen2026-07-01T00:00:00.000ZBackreaction of stimulated Hawking radiation in an optical analoguehttps://www.pharmaradar360.com/article/hadean-bridgmanite-in-the-source-of-a-present-day-ocean-island-62d5d08fe12012f1Pharma Surgeen2026-07-01T00:00:00.000ZHadean bridgmanite in the source of a present-day ocean islandhttps://www.pharmaradar360.com/article/targeted-enzyme-discovery-using-metal-coordination-mining-49fdb2e180d2bbdePharma Surgeen2026-07-01T00:00:00.000ZTargeted enzyme discovery using metal-coordination mininghttps://www.pharmaradar360.com/article/tin-perovskite-transistors-stabilized-through-volatile-coordination-8663a9d11647918bPharma Surgeen2026-07-01T00:00:00.000ZTin perovskite transistors stabilized through volatile coordinationhttps://www.pharmaradar360.com/article/a-secreted-endosymbiont-protein-essential-for-colonizing-host-cells-f9f3ec04851d878ePharma Surgeen2026-07-01T00:00:00.000ZA secreted endosymbiont protein essential for colonizing host cellshttps://www.pharmaradar360.com/article/directly-probing-the-carrier-transfer-length-in-2d-material-transistors-49cdcb7976499113Pharma Surgeen2026-07-01T00:00:00.000ZDirectly probing the carrier transfer length in 2D-material transistorshttps://www.pharmaradar360.com/article/replication-stress-induced-chromatin-loops-protect-fork-stability-9de9c0997266c57cPharma Surgeen2026-07-01T00:00:00.000ZReplication-stress-induced chromatin loops protect fork stabilityhttps://www.pharmaradar360.com/article/steatosis-shapes-prognosis-defining-liver-metastasis-heterogeneity-in-crc-b62939bd136a8e06Pharma Surgeen2026-07-01T00:00:00.000ZSteatosis shapes prognosis-defining liver metastasis heterogeneity in CRChttps://www.pharmaradar360.com/article/restoring-cortical-disinhibition-improves-huntington-s-disease-phenotypes-2b2daed906b30426Pharma Surgeen2026-07-01T00:00:00.000ZRestoring cortical disinhibition improves Huntington’s disease phenotypeshttps://www.pharmaradar360.com/article/dual-tumour-myeloid-targeting-of-glioblastoma-with-gpnmb-car-t-cells-d1e99c26fa01c07dPharma Surgeen2026-07-01T00:00:00.000ZDual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cellshttps://www.pharmaradar360.com/article/harmonizing-standards-and-resources-for-the-medical-genome-e67247ca1a78761ePharma Surgeen2026-07-01T00:00:00.000ZHarmonizing standards and resources for the medical genomehttps://www.pharmaradar360.com/article/towards-the-construction-of-a-virtual-yeast-f6b696b20c95bca3Pharma Surgeen2026-07-01T00:00:00.000ZTowards the construction of a virtual yeasthttps://www.pharmaradar360.com/article/aerosols-and-hydrocarbons-in-the-atmosphere-of-a-white-dwarf-planet-03dfb62ed0dac5d4Pharma Surgeen2026-07-01T00:00:00.000ZAerosols and hydrocarbons in the atmosphere of a white dwarf planethttps://www.pharmaradar360.com/article/connecting-single-cell-transcriptomes-to-projectomes-in-the-mouse-visual-cortex-5737c45b8e37e944Pharma Surgeen2026-07-01T00:00:00.000ZConnecting single-cell transcriptomes to projectomes in the mouse visual cortexhttps://www.pharmaradar360.com/article/togetherness-how-co-operation-built-the-world-35914a157346e0e7Pharma Surgeen2026-07-01T00:00:00.000ZTogetherness: How co-operation built the worldhttps://www.pharmaradar360.com/article/circular-rna-guides-exon-skipping-in-dmd-2dc7e1698550b6bbPharma Surgeen2026-07-01T00:00:00.000ZCircular RNA guides exon skipping in DMDhttps://www.pharmaradar360.com/article/r-amp-d-productivity-trends-for-biopharma-companies-in-asia-and-emerging-markets-ac420314fd6a69f4Pharma Surgeen2026-07-01T00:00:00.000ZR&D productivity trends for biopharma companies in Asia and emerging marketshttps://www.pharmaradar360.com/article/growth-in-clinical-research-capability-in-china-and-impact-on-the-pharmaceutical-a7d79bebd4ebe04ePharma Surgeen2026-07-01T00:00:00.000ZGrowth in clinical research capability in China and impact on the pharmaceutical sectorhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-7c64bdc9ee38613bPharma Surgeen2026-07-01T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-cca4d3daa179bf8fPharma Surgeen2026-07-01T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-9b8a118b1c3060d7Pharma Surgeen2026-07-01T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-6ee34af4d561a88dPharma Surgeen2026-07-01T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-2c7398437126c681Pharma Surgeen2026-07-01T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-37ba6e1d0f393fbePharma Surgeen2026-07-01T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-fdb8347c8d9a4893Pharma Surgeen2026-07-01T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-9dea458a8b3d2d02Pharma Surgeen2026-07-01T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-abea927103de2e80Pharma Surgeen2026-07-01T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-66850a936072b4b4Pharma Surgeen2026-07-01T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-86300e230ce9781fPharma Surgeen2026-07-01T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-1dee215d44d7f043Pharma Surgeen2026-07-01T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-cca34484d4eb46f4Pharma Surgeen2026-07-01T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-a6d1c144e71b2fd8Pharma Surgeen2026-07-01T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/more-precise-fire-extinguishing-from-the-air-using-simulation-and-sensor-data-0be4677f1d981cbcPharma Surgeen2026-07-01T00:00:00.000ZMore Precise Fire Extinguishing From the Air Using Simulation and Sensor Datahttps://www.pharmaradar360.com/article/green-lime-reducing-carbon-emissions-in-the-construction-materials-industry-e26357151fcdd281Pharma Surgeen2026-07-01T00:00:00.000ZGreen Lime: Reducing Carbon Emissions in the Construction Materials Industryhttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-temporary-placement-of-5-6-dichloro-brorphine-01846c2ca35e85ccPharma Surgeen2026-07-01T00:00:00.000ZSchedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Acthttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-4bbcaf2d4179db44Pharma Surgeen2026-07-01T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Productshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-ec0fe1e65cfa659bPharma Surgeen2026-07-01T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/lists-of-designated-primary-medical-care-mental-health-and-dental-health-profess-9da79d986a49fa2ePharma Surgeen2026-07-01T00:00:00.000ZLists of Designated Primary Medical Care, Mental Health, and Dental Health Professional Shortage Areashttps://www.pharmaradar360.com/article/notice-of-proposed-purchased-referred-care-delivery-area-redesignation-for-yslet-4760d01d48eca2b2Pharma Surgeen2026-07-01T00:00:00.000ZNotice of Proposed Purchased/Referred Care Delivery Area Redesignation for Ysleta Del Sur Pueblohttps://www.pharmaradar360.com/article/modification-of-living-organ-donation-reimbursement-program-eligibility-guidelin-17d3099fdb331868Pharma Surgeen2026-07-01T00:00:00.000ZModification of Living Organ Donation Reimbursement Program Eligibility Guidelines in Response To Honor Our Living Donors Acthttps://www.pharmaradar360.com/article/the-federal-demonstration-partnership-phase-viii-notice-8f65a17e29bbe00aPharma Surgeen2026-07-01T00:00:00.000ZThe Federal Demonstration Partnership; Phase VIII Noticehttps://www.pharmaradar360.com/article/rural-health-innovation-and-transformation-technical-assistance-8fcfeb01fe6f47d6Pharma Surgeen2026-07-01T00:00:00.000ZRural Health Innovation and Transformation Technical Assistancehttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-cc2c9f220cf027c7Pharma Surgeen2026-07-01T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: National Marrow Donor Program Patient Support Center Surveyhttps://www.pharmaradar360.com/article/drug-label-update-evereden-kids-mineral-sunscreen-spf-30-bd2e8f7ef3f473aaPharma Surgeen2026-07-01T00:00:00.000ZDrug label update: Evereden Kids Mineral Sunscreen SPF 30https://www.pharmaradar360.com/article/drug-label-update-metformin-hydrochloride-046d4a31cf7b826fPharma Surgeen2026-07-01T00:00:00.000ZDrug label update: METFORMIN HYDROCHLORIDEhttps://www.pharmaradar360.com/article/drug-label-update-guna-virus-3eb3bf9cba150338Pharma Surgeen2026-07-01T00:00:00.000ZDrug label update: GUNA-VIRUShttps://www.pharmaradar360.com/article/drug-label-update-metformin-hydrochloride-er-6fc4ef2014cdb350Pharma Surgeen2026-07-01T00:00:00.000ZDrug label update: METFORMIN HYDROCHLORIDE ERhttps://www.pharmaradar360.com/article/stratneuro-studentkaren-550fb8509113c0daPharma Surgeen2026-07-01T00:00:00.000ZStratNeuro Studentkårenhttps://www.pharmaradar360.com/article/ki-forskare-tilldelas-internationellt-stipendium-for-melanomforskning-0e1ccebcdba9eda4Pharma Surgeen2026-07-01T00:00:00.000ZKI‑forskare tilldelas internationellt stipendium för melanomforskning